Levoketoconazole
FDA-approved product (tablet, oral), marketed as Recorlev.
- Registered studies
- 6
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adrenal gland disease
- Adrenal gland hyperfunction
- Cushing syndrome
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Anticorticosteroids
- FDA pharmacologic class
- Cortisol Synthesis Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis81.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
6registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Levoketoconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Bioavailability of Levoketoconazole and Ketoconazole Tablets
NCT04212000 · start 2019-12-16
Registered record
- Registry ID
- NCT04212000
- Conditions
- Healthy
- Interventions
- Levoketoconazole; Ketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-12-16
- Completion
- 2020-01-23
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionLevoketoconazole; KetoconazolePhasePhase 1Registry statusCompletedDrug Interaction Study of Levoketoconazole and Metformin
NCT03880825 · start 2019-03-28
Registered record
- Registry ID
- NCT03880825
- Conditions
- Healthy Subjects
- Interventions
- Metformin 500 mg Oral Tablet; Levoketoconazole 150 - 600 mg (BID)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2019-03-28
- Completion
- 2019-05-03
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionMetformin 500 mg Oral Tablet; Levoketoconazole 150 - 600 mg (BID)PhasePhase 1Registry statusCompletedOpen-label Treatment in Cushing's Syndrome
NCT03621280 · start 2019-01-07
Registered record
- Registry ID
- NCT03621280
- Conditions
- Cushing Syndrome; Cushing Disease
- Interventions
- Levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2019-01-07
- Completion
- 2022-12-31
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCushing Syndrome; Cushing DiseaseInterventionLevoketoconazolePhasePhase 3Registry statusCompletedLevoketoconazole Food Effect Study in Healthy Subjects
NCT03768388 · start 2018-11-30
Registered record
- Registry ID
- NCT03768388
- Conditions
- Healthy Subjects
- Interventions
- levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-11-30
- Completion
- 2018-12-24
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionlevoketoconazolePhasePhase 1Registry statusCompletedA Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT03277690 · start 2017-09-26
Registered record
- Registry ID
- NCT03277690
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Levoketoconazole; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-09-26
- Completion
- 2020-08-31
- Enrolment
- 84
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndogenous Cushing's SyndromeInterventionLevoketoconazole; PlaceboPhasePhase 3Registry statusCompletedTreatment for Endogenous Cushing's Syndrome
NCT01838551 · start 2014-08
Registered record
- Registry ID
- NCT01838551
- Conditions
- Endogenous Cushing's Syndrome
- Interventions
- Levoketoconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-08
- Completion
- 2018-11
- Enrolment
- 94
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndogenous Cushing's SyndromeInterventionLevoketoconazolePhasePhase 3Registry statusCompleted